Zhong, W-Z : rechercher sur Z-Library

Le plus grand référentiel d'articles scientifiques au monde. 70,000,000+ d'articles gratuitement.

Don't use scam websites

Livres
Articles (10)
Les plus populaires
Liste
- Liste
- Tableau

1

In vitro effect of levamisole on the cell viability, phagocytosis and respiratory burst of Barbel chub (Squaliobarbus curriculus) macrophages

G.-F. LI, L-B. LIU, Y-L. TAN, L-Z. LIU, H-Z. DENG, H. WAN, W-Z. ZHONG, S-J. CHEN

Journal:

Aquaculture Nutrition

Année:

2011

Langue:

english

Fichier:

PDF, 910 KB

english, 2011

2

High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients

Qiao, G-B, Wu, Y-L, Yang, X-N, Zhong, W-Z, Xie, D, Guan, X-Y, Fischer, D, Kolberg, H-C, Kruger, S, Stuerzbecher, H-W

Journal:

British Journal of Cancer

Année:

2005

Langue:

english

Fichier:

PDF, 192 KB

english, 2005

3

454P Efficacy of crizotinib in NSCLC with concomitant ALK fusion and c-MET overexpression

Chen, R-L., Lou, N-N., Yang, J-J., Zhang, X-C., Chen, H-J., Su, J., Zhou, Q., Tu, H-Y., Xie, Z., Zhong, W-Z., Guo, W-B., Wu, Y-L.

Journal:

Annals of Oncology

Année:

2016

Langue:

english

Fichier:

PDF, 44 KB

english, 2016

4

443O EGFR mutations are associated with unfavourable efficacy to anti-PD1 therapy in NSCLC

Liu, S-Y., Dong, Z., Zhong, W-Z., Wu, Y-L.

Journal:

Annals of Oncology

Année:

2016

Langue:

english

Fichier:

PDF, 47 KB

english, 2016

5

LBA48_PRCTONG 1103: Erlotinib versus gemcitabine plus cisplatin as neo-adjuvant treatment for stage IIIA-N2 EGFR-mutation non-small cell lung cancer (EMERGING): A randomised study

Zhong, W-Z, Wu, Y-L, Chen, K-N, Chen, C, Gu, C-D, Wang, Q, Wang, J, Mao, W, Qiao, G-B, Cheng, Y, Xu, L, Wang, C-L, Chen, M-W, Yang, X-N, Chen, H-J, Yang, H-H, Yang, J-J, Zhou, Q

Journal:

Annals of Oncology

Année:

2018

Langue:

english

Fichier:

PDF, 99 KB

english, 2018

6

395O Potential predictive value for adjuvant PD-1 blockade based on histologic subtype in resected lung adenocarcinoma

Dong, Z-Y., Zhong, W-Z., Liu, S-Y., Xie, Z., Wu, S-P., Wu, Y-L.

Journal:

Annals of Oncology

Année:

2016

Langue:

english

Fichier:

PDF, 69 KB

english, 2016

7

416P Typical morphological features revealed unfavorable survival benefits in high-grade neuroendocrine carcinomas

Zhai, H-R., Zhang, J-T., Yan, L-X., Zhang, C., Su, J., Dong, S., Nie, Q., Liao, R-Q., Jiang, B-Y., Yang, X-N., Wu, Y-L., Zhong, W-Z.

Journal:

Annals of Oncology

Année:

2016

Fichier:

PDF, 69 KB

2016

8

459P Comparison of predictive value betweenmetabolic tumor volume and RECIST 1.1 assessed by 18F-FDG PET-CT in patients with lung cancer

Lin, J-T., Hou, Q-Y., Dong, Z-Y., Zhong, W-Z., Li, Y-S., Wu, Y-L.

Journal:

Annals of Oncology

Année:

2016

Fichier:

PDF, 73 KB

2016

9

439O Tracking spatiotemporal T790M heterogeneity in patients with EGFR-mutant advanced NSCLC after acquired resistance to EGFR TKIs

Zhang, Y-C., Pi, C., Ke, E-E., Chen, Z-H., Su, J., Dong, Z-Y., Xu, C-R., Yan, H-H., Tu, H-Y., Zhong, W-Z., Zhang, X-C., Yang, J-J., Yang, X-N., Zhou, Q., Wu, Y-L.

Journal:

Annals of Oncology

Année:

2016

Fichier:

PDF, 77 KB

2016

10

1441PDA comprehensive model of genetic-features predicts outcome of personalized adjuvant treatment in resected EGFR-mutant stage II-IIIA NSCLC: Results from a phase III trial (CTONG 1104-ADJUVANT)

Wu, Y-L, Liu, S-Y, Wang, Q, Mao, W, Wu, L, Shen, Y, Cheng, Y, Chen, C, Xu, L, Wang, J, Liu, H-X, Bao, H, Chen, Y-D, Zhang, X, Chen, Z-H, Yan, H-H, Yang, J-J, Shao, Y W, Zhou, Q, Zhong, W-Z

Journal:

Annals of Oncology

Année:

2019

Fichier:

PDF, 79 KB

2019